A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Seagen Inc.
Eli Lilly and Company
Pfizer
Pfizer
A2 Biotherapeutics Inc.
Revolution Medicines, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Colorado, Denver
City of Hope Medical Center
Novartis
Var2 Pharmaceuticals
City of Hope Medical Center
Chongqing Precision Biotech Co., Ltd
A2 Biotherapeutics Inc.
Elicio Therapeutics
ModeX Therapeutics, An OPKO Health Company
Shanghai Cingularbio Co. Ltd
Columbia University
University of Arizona
Stanford University
Peter MacCallum Cancer Centre, Australia
Mayo Clinic
Rutgers, The State University of New Jersey
Stanford University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chongqing Precision Biotech Co., Ltd
UTC Therapeutics Inc.
Washington University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
Chongqing Precision Biotech Co., Ltd
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Klus Pharma Inc.
Eastern Cooperative Oncology Group
Qianfoshan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Novartis
MacroGenics
Wake Forest University Health Sciences
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Institut Bergonié
Abramson Cancer Center at Penn Medicine
Fox Chase Cancer Center
City of Hope Medical Center
Stanford University